Nanomedicine is the medical application of nanotechnology. Nanomedicine ranges from the medical applications of nanomaterials and biological devices, to nanoelectronic biosensors, and even possible future applications of molecular nanotechnology such as biological machines.
Paris-based Nanobiotix a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, recently announced the expansion and acceleration of its clinical development activities.These include:
- Acceleration of the head and neck cancer program. Phase I/II data will be presented at ASCO in June
- Expansion of Nanobiotix’s Immuno-Oncology program into patients focused on the objective of turning cold tumors into hot tumors. Nanobiotix wil present the first clinical datafrom this programmid year
Additionally, before the end of 2017, Nanobiotix aims to complete patient recruitment for the Phase I partin liver cancers, and may proceed to select the patient population for the dose-expansion part of the trial (PhaseII).In parallel, Nanobiotix is accelerating its market preparations for NBTXR3’s launch on the European market. The firstapproval(CE marking)in Europe is expected in H2 2017.
NBTXR3 is being evaluated in: soft tissue sarcoma (STS), head and neck cancers, prostate cancer, and liver cancers (primary and metastases).Additionally,head and neck cancer and rectal cancer trials led by Nanobiotix’s Taiwanese partner, PharmaEngine, are underway in the Asia Pacific region. The Company has filed in August 2016 for market approval (CE Marking) in Europe for its lead product NBTXR3.
Levy, who has been working in the nanotechnology field for two decades, spoke to Bioscience Technology about the company’s lead product NBTXR3, and how it can enhance radiotherapy for a number of indications currently in clinical trials.The company’s first foray is into radiotherapy, also known as radiation therapy, and was chosen for a few reasons, Levy said. For one, it is one of the most widely used treatments in oncology, with 60 percent of all cancer patients receiving radiotherapy during treatment.
Secondly, it is a patient population that are usually untapped by the pharmaceutical or biotech companies, so there is a widely open market with a patient population that does not have many treatment opportunities outside of radiotherapy. Finally, when a physician wants to eradicate a tumor with radiation, the x-ray beam also has to go through healthy tissue too, often causing damage, which limits the dose that can be delivered.
Levy believes their novel approach has the potential to impact many cancers.“From our perspective, we think that the beauty of nanotechnology is that you bring a completely different mode of action into the oncology field,” he said.With a biological approach,
Levy said, one could take hundreds of cancer cells, some of which will be destroyed by chemo, some that will not be destroyed at all because they don’t express the right receptor, and some that will start dying but will then develop some resistance and regrow again.“When you use physics, you bring something that a cancer cell cannot resist,” he said.